The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Can postendoscopic retrograde cholangiopancreatography pancreatitis be prevented by a pharmacological approach?

  • Cheon, Young Koog (Digestive Disease Center, Department of Internal Medicine, Konkuk University School of Medicine)
  • Published : 2013.03.01
⟨ Previous Next ⟩

Abstract

Acute pancreatitis remains the most frequent complication of endoscopic retrograde cholangiopancreatography (ERCP), with reported incidence rates that have changed little over several decades. Patient- and procedure-related risk factors for post-ERCP pancreatitis (PEP) are well-defined. Effective measures to prevent PEP have been identified, including improvements in cannulation techniques and pancreatic stenting, as well as pharmacological intervention. Pharmacotherapy has been widely studied in the prevention of PEP, but the effect in averting PEP has been inconclusive. Although pharmacological prophylaxis is appealing, attempts to find an ideal drug are incomplete. Most available data on the efficacy of pharmacological agents for PEP prophylaxis have been obtained from patients at average risk for PEP. However, recently, a randomized prospective controlled trial of rectal nonsteroidal anti-inflammatory drugs (NSAIDs) to prevent PEP in high-risk patients was published. The results revealed that rectal indomethacin reduced the incidence of PEP significantly. Thus, rectal administration of diclofenac or indomethacin immediately before or after ERCP is used routinely to prevent PEP. However, additional studies with NSAIDs using large numbers of subjects are necessary to confirm the prophylactic effect of these drugs and to establish whether they act synergistically with other prophylactic interventions, including pancreatic stenting.

Keywords

References

  1. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996;335:909-918. https://doi.org/10.1056/NEJM199609263351301
  2. Masci E, Mariani A, Curioni S, Testoni PA. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. Endoscopy 2003;35:830-834. https://doi.org/10.1055/s-2003-42614
  3. Cheon YK, Cho KB, Watkins JL, et al. Frequency and severity of post-ERCP pancreatitis correlated with extent of pancreatic ductal opacification. Gastrointest Endosc 2007;65:385-393. https://doi.org/10.1016/j.gie.2006.10.021
  4. Chen YK, Foliente RL, Santoro MJ, Walter MH, Collen MJ. Endoscopic sphincterotomy-induced pancreatitis: increased risk associated with nondilated bile ducts and sphincter of Oddi dysfunction. Am J Gastroenterol 1994;89:327-333.
  5. Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004;59:845-864. https://doi.org/10.1016/S0016-5107(04)00353-0
  6. Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012;366:1414-1422. https://doi.org/10.1056/NEJMoa1111103
  7. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991;37:383-393. https://doi.org/10.1016/S0016-5107(91)70740-2
  8. Murray WR. Reducing the incidence and severity of post ERCP pancreatitis. Scand J Surg 2005;94:112-116. https://doi.org/10.1177/145749690509400206
  9. Dumonceau JM, Andriulli A, Deviere J, et al. European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis. Endoscopy 2010;42:503-515. https://doi.org/10.1055/s-0029-1244208
  10. Nishijima MK, Takezawa J, Taenaka N, Shimada Y, Yoshiya I. Application of HPLC measurement of plasma concentration of gabexate mesilate. Thromb Res 1983;31:279-284. https://doi.org/10.1016/0049-3848(83)90330-4
  11. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography: gabexate in digestive endoscopy: Italian Group. N Engl J Med 1996;335:919-923. https://doi.org/10.1056/NEJM199609263351302
  12. Andriulli A, Leandro G, Niro G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 2000;51:1-7. https://doi.org/10.1016/S0016-5107(00)70377-4
  13. Andriulli A, Clemente R, Solmi L, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002;56:488-495. https://doi.org/10.1016/S0016-5107(02)70431-8
  14. Fujishiro H, Adachi K, Imaoka T, et al. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study. J Gastroenterol Hepatol 2006;21:1065-1069. https://doi.org/10.1111/j.1440-1746.2006.04085.x
  15. Tsujino T, Komatsu Y, Isayama H, et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol 2005;3:376-383. https://doi.org/10.1016/S1542-3565(04)00671-8
  16. Ueki T, Otani K, Kawamoto K, et al. Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial. J Gastroenterol 2007;42:161-167. https://doi.org/10.1007/s00535-006-1986-8
  17. Yoo JW, Ryu JK, Lee SH, et al. Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial. Pancreas 2008;37:366-370. https://doi.org/10.1097/MPA.0b013e31817f528f
  18. Abdel Aziz AM, Lehman GA. Pancreatitis after endoscopic retrograde cholangio-pancreatography. World J Gastroenterol 2007;13:2655-2668. https://doi.org/10.3748/wjg.v13.i19.2655
  19. Andriulli A, Caruso N, Quitadamo M, et al. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study. JOP 2003;4:41-48.
  20. Vila JJ, Jimenez FJ, Prieto C, Borobio E, Juanmartinena JF, Borda F. Utility of bolus somatostatin administration in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a controlled, nonrandomized study. Gastroenterol Hepatol 2006;29:231-236. https://doi.org/10.1157/13085969
  21. Sternlieb JM, Aronchick CA, Retig JN, et al. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol 1992;87:1561-1566.
  22. Binmoeller KF, Dumas R, Harris AG, Delmont JP. Effect of somatostatin analog octreotide on human sphincter of Oddi. Dig Dis Sci 1992;37:773-777. https://doi.org/10.1007/BF01296438
  23. Arcidiacono R, Gambitta P, Rossi A, Grosso C, Bini M, Zanasi G. The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Endoscopy 1994;26:715-718. https://doi.org/10.1055/s-2007-1009081
  24. Tulassay Z, Dobronte Z, Pronai L, Zagoni T, Juhasz L. Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography. Aliment Pharmacol Ther 1998;12:1109-1112. https://doi.org/10.1046/j.1365-2036.1998.00414.x
  25. Staritz M, Poralla T, Ewe K, Meyer zum Buschenfelde KH. Effect of glyceryl trinitrate on the sphincter of Oddi motility and baseline pressure. Gut 1985;26:194-197. https://doi.org/10.1136/gut.26.2.194
  26. Bang UC, Nojgaard C, Andersen PK, Matzen P. Metaanalysis: nitroglycerin for prevention of post-ERCP pancreatitis. Aliment Pharmacol Ther 2009;29:1078-1085. https://doi.org/10.1111/j.1365-2036.2009.03978.x
  27. Shao LM, Chen QY, Chen MY, Cai JT. Nitroglycerin in the prevention of post-ERCP pancreatitis: a meta-analysis. Dig Dis Sci 2010;55:1-7. https://doi.org/10.1007/s10620-008-0709-9
  28. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction: Sildenafil Study Group. N Engl J Med 1998;338:1397-1404. https://doi.org/10.1056/NEJM199805143382001
  29. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-2157. https://doi.org/10.1056/NEJMoa050010
  30. Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005;112:2980-2985.
  31. Eherer AJ, Schwetz I, Hammer HF, et al. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut 2002;50:758-764. https://doi.org/10.1136/gut.50.6.758
  32. Cheon YK, Cho YD, Moon JH, et al. Effects of vardenafil, a phosphodiesterase type-5 inhibitor, on sphincter of Oddi motility in patients with suspected biliary sphincter of Oddi dysfunction. Gastrointest Endosc 2009;69:1111-1116. https://doi.org/10.1016/j.gie.2008.07.014
  33. Oh HC, Cheon YK, Cho YD, Do JH. Use of udenafil is not associated with a reduction in post-ERCP pancreatitis: results of a randomized, placebo-controlled, multicenter trial. Gastrointest Endosc 2011;74:556-562. https://doi.org/10.1016/j.gie.2011.04.047
  34. Prat F, Amaris J, Ducot B, et al. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc 2002;56:202-208. https://doi.org/10.1016/S0016-5107(02)70178-8
  35. Sand J, Nordback I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion 1993;54:105-111. https://doi.org/10.1159/000201021
  36. Makela A, Kuusi T, Schroder T. Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro. Scand J Clin Lab Invest 1997;57:401-407. https://doi.org/10.3109/00365519709084587
  37. Niederau C, Schulz HU. Current conservative treatment of acute pancreatitis: evidence from animal and human studies. Hepatogastroenterology 1993;40:538-549.
  38. Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 2003;124:1786-1791. https://doi.org/10.1016/S0016-5085(03)00384-6
  39. Cheon YK, Cho KB, Watkins JL, et al. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial. Gastrointest Endosc 2007;66:1126-1132. https://doi.org/10.1016/j.gie.2007.04.012
  40. van Hoogdalem EJ, de Boer AG, Breimer DD. Pharmacokinetics of rectal drug administration, part II: clinical applications of peripherally acting drugs, and conclusions. Clin Pharmacokinet 1991;21:110-128. https://doi.org/10.2165/00003088-199121020-00003
  41. van der Marel CD, Anderson BJ, Romsing J, Jacqz-Aigrain E, Tibboel D. Diclofenac and metabolite pharmacokinetics in children. Paediatr Anaesth 2004;14:443-451. https://doi.org/10.1111/j.1460-9592.2004.01232.x
  42. Deviere J, Le Moine O, Van Laethem JL, et al. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001;120:498-505. https://doi.org/10.1053/gast.2001.21172
  43. Morrow JB, Zuccaro G Jr, Conwell DL, et al. Sedation for colonoscopy using a single bolus is safe, effective, and efficient: a prospective, randomized, double-blind trial. Am J Gastroenterol 2000;95:2242-2247. https://doi.org/10.1111/j.1572-0241.2000.02308.x
  44. Sherman S, Cheng CL, Costamagna G, et al. Efficacy of recombinant human interleukin-10 in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. Pancreas 2009;38:267-274. https://doi.org/10.1097/MPA.0b013e31819777d5
  45. Budzynska A, Marek T, Nowak A, Kaczor R, Nowakowska-Dulawa E. A prospective, randomized, placebocontrolled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy 2001;33:766-772. https://doi.org/10.1055/s-2001-16520
  46. De Palma GD, Catanzano C. Use of corticosteriods in the prevention of post-ERCP pancreatitis: results of a controlled prospective study. Am J Gastroenterol 1999;94:982-985. https://doi.org/10.1111/j.1572-0241.1999.999_u.x
  47. Sherman S, Blaut U, Watkins JL, et al. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study. Gastrointest Endosc 2003;58:23-29. https://doi.org/10.1067/mge.2003.307
  48. Toulon P, Chadeuf G, Bouillot JL, et al. Involvement of heparin cofactor II in chymotrypsin neutralization and in the pancreatic proteinase-antiproteinase interaction during acute pancreatitis in man. Eur J Clin Invest 1991;21:303-309. https://doi.org/10.1111/j.1365-2362.1991.tb01374.x
  49. Barkay O, Niv E, Santo E, Bruck R, Hallak A, Konikoff FM. Low-dose heparin for the prevention of post-ERCP pancreatitis: a randomized placebo-controlled trial. Surg Endosc 2008;22:1971-1976. https://doi.org/10.1007/s00464-007-9738-2
  50. Rabenstein T, Fischer B, Wiessner V, et al. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc 2004;59:606-613. https://doi.org/10.1016/S0016-5107(04)00159-2

Cited by

  1. Endoscopic papillectomy, single-centre experience vol.28, pp.11, 2014, https://doi.org/10.1007/s00464-014-3596-5
  2. Rectal indomethacin versus placebo to reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography: results of a controlled clinical trial vol.15, pp.None, 2015, https://doi.org/10.1186/s12876-015-0314-2
  3. Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a randomized multicenter study vol.30, pp.5, 2013, https://doi.org/10.3904/kjim.2015.30.5.602
  4. The effect of prophylactic peripapillary administration of methylprednisolone in reducing the risk and severity of postendoscopic retrograde cholangiopancreatography pancreatitis: A double blind clini vol.20, pp.9, 2013, https://doi.org/10.4103/1735-1995.170599
  5. Comparison of rectal indomethacin, diclofenac, and naproxen for the prevention of post endoscopic retrograde cholangiopancreatography pancreatitis vol.29, pp.3, 2013, https://doi.org/10.1097/meg.0000000000000787
  6. Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment vol.25, pp.29, 2013, https://doi.org/10.3748/wjg.v25.i29.4019